ACTA ENDOCRINOLOGICA (BUC)

The International Journal of Romanian Society of Endocrinology / Registered in 1938

in Web of Science Master Journal List

Acta Endocrinologica(Bucharest) is live in PubMed Central

Journal Impact Factor - click here.

Year Volume Issue First page
10.4183/aeb.
Author
Title
Abstract/Title
From through

  • General Endocrinology

    Mihaescu G, Olinescu R, Oancea F

    Metabolic syndrome may be improved following a long-time administration of a nutritive supplement containing embryonary peptides

    Acta Endo (Buc) 2005 1(3): 263-270 doi: 10.4183/aeb.2005.263

    Abstract References
    Metabolic Syndrome (MS) is a polymorph disease with a high frequency especially in older age. Any randomized study with nonhospitalized subjects might include those bearing MS, that greatly influenced the final results. Eighty subjects aged 50-75 years (38 men and 42 women) had consumed daily 4 caps of purified Embryonary Peptides (EP) for 60 days. The samples of blood from each subject were obtained before and after administration. Therefore, each subject was his own control. In all subjects, after administration, regardless of the MS presence, total cholesterol and LDL-cholesterol had decreased approximately 30 % as compared with the initial values. Significant decreases of insulin and cortisol were also observed, but associated with modifications of PSA, CEA and IGF-l. The magnitude of these changes was lower in subjects with MS. The long-lasting modifications induced by EP seem to have an adaptive-regulatory character, affecting the lipid metabolism (already modified in MS), as well as some pathways from steroid biosynthesis. Thus, EP might act similarly to some stimulatory factors, such as IGF-1, in a reversible stage of MS.
    1. Reaven GM. Role of insulin resistance in human diseases. Diabetes 1988; 37: 1595-1599. [CrossRef]
    2. Despres JP. Potential contribution of metformin to the management of cardio-vascular risk in patients with abdominal obesity and type 2 diabetes. Diab. Metab. 2003; 29: 6S53-6S59.
    3. Hancu N., Roman G., Nita C. et al. Metabolic Syndrome - Practical Approach. Roman. J. Inter, Med. 2004; 42(2): 237-246.
    4. Mota M., Panus C., Mota E. et al. Metabolic Syndrome - a multifaced disease. Roman. J. Intern. Med. 2004; 42(2): 247-256.
    5. Gruia IM. Olinescu R., Mihaescu G. The modification of oxidative stress in elderly after Orgasel and Humanofort treatment. Infomedica 1997; 11: 40-44.
    6. Mihaescu G., Olinescu R., Oancea F., Significant modifications of lipid metabolism in aged persons following the administration of a nutritive supplement. Rom. J. Intern. Med. 2006 - in press.
    7. Jaffiel C. Le Syndrome Polymetabolique ou Obesite Maligne. Roum. J. Endocrinol. Metabolism, 2005; 4(3): 14-20.
    8. Vaughan CJ., Murphy MB., Buckley BM., Statins do more than lower cholesterol. Lancet l996; 348-352.
    9. Serpoi G., Cucu C., Transaminases are significantly increased in patients with metabolic syndrome when compared with obese controls. Acta Endocrinologica 2005; 1(1): 19-30. [CrossRef]
    10. Olinescu R., Smith TL., Physiologic Effects of Oxidative Stress: Aging, in: Olinescu R. and Smith TL, Free Radicals in Medicine, Nova Science Publ.Inc. New York, 2002; 120-126.
    11. Kummerow FA, Olinescu R., Fleischer L. et al. The relationship of oxidized lipids to coronary artery stenosis. Atherosclerosis, 2000; 149: 181-190.
    12. Marcus MA., White GC., Insulin sensitivity and serum triglyceride level in obese white and black women. Metabolism, 1999; 48: 143-149.
    13. Czeh MP. New perspectives on the mechanism of insulin action. Recent Progress Hormone Res. 1984; 40: 347-360.
    14. Landin WS., Lappas G., Serum IGF-1 in random population sample of men and women. Clin. Endocrinol. Oxford, 1994; 41: 351-357.
  • General Endocrinology

    Csép K, Gyongyi Dudutz, Marta Vitay, Pascanu I, Banescu C, Koranyi L, Rosivall L

    The Relationship Between The PRO12ALA Polymorphism Of The PPAR?2 Gene And The Metabolic Syndrome In A Population Of Central Romania Diagnosed According To The Idf Criteria

    Acta Endo (Buc) 2008 4(3): 263-271 doi: 10.4183/aeb.2008.263

    Abstract
    The nuclear receptor coding PPARγ2 (PEROXISOME PROLIFERATORACTIVATED RECEPTOR-GAMMA; *601487) gene influences the lipid and carbohydrate metabolism via multiple pathways and is a candidate for the metabolic syndrome. In this paper we studied the relationship of the CCG (Pro) → GCG (Ala) polymorphism of the gene with the metabolic syndrome diagnosed according to the criteria recommended by the International Diabetes Federation (IDF) in 2005, in a population from central Romania. We have carried out a case-control study on 144 patients and 73 control subjects. Routine biochemical assays have been carried out, fasting insulinemia was measured by ELISA, and insulin sensitivity was assessed by calculating the HOMA and QUICKI indices. Genetic analysis was done by PCR followed by digestion with the restriction enzyme BstU I. The results show that the Pro12 allele had a higher frequency in the group of patients as compared to the healthy controls (76 vs. 65.7%, p<0.05). The risk for developing the metabolic syndrome in the presence of the Pro12 allele in a homozygous combination was found to be low but statistically significant (PP vs. PA + AA: OR = 1.98, CI 95% 1.04 -3.78, p = 0.046). In conclusion, in the local population, the Pro12 allele of the PPARG2 gene seems to contribute to the hereditary predisposition of the metabolic syndrome diagnosed according to the recommendations of the IDF, most likely as part of a polygenic system. Probably the absence of the protective Ala12 allele increases the risk for developing the disease.
  • Images in Endocrinology

    Niculescu DA, Dumitrascu A, Lica I

    Neck tumoral swelling in an endemic iodine deficiency area

    Acta Endo (Buc) 2010 6(2): 263-263 doi: 10.4183/aeb.2010.263

  • Editorial

    Grigorie D

    Hip Fracture Epidemiology in Romania and the Development of the Romanian FRAX Model

    Acta Endo (Buc) 2011 7(2): 263-266 doi: 10.4183/aeb.2011.263

  • Notes & Comments

    Kocak MZ, Aktas G, Atak B, Bilgin S, Kurtkulagi O, Duman TT, Ozcil IE

    The Association between Vitamin D Levels and Handgrip Strength in Elderly Men

    Acta Endo (Buc) 2020 16(2): 263-266 doi: 10.4183/aeb.2020.263

    Abstract
    Context. Vitamin D is a steroid hormone that acts by binding to the vitamin D receptor (VDR) found in many tissues. According to the long-term mechanism, vitamin D causes the proliferation and differentiation of muscle cells by gene transcription. Objective. We aimed to evaluate the relationship between muscle strength and serum vitamin D levels in elderly men. Design. Cross-sectional study. Subjects and Methods. Male patients over age 50 were included in the study. Study population was divided into 2 groups with handgrip strength according to body mass index, either as subjects with weak or with normal handgrip strength test (HGST). Vitamin D levels and other variables compared between weak and normal groups. Results. Vitamin D level of weak and normal groups were 7.5 (3-19.9) μg/L, and 11.6 (11.6-34.9) μg/L, which means significant reduced vitamin D levels in weakness group (p=0.01). Vitamin D levels were significantly correlated with HGST levels (r:0.362, p=0.001). Vitamin D levels were found to be an independent predictor of weakness according to HGST in logistic regression analysis (OR: 0.453, 95% Cl:0.138-0.769, p=0.05). Conclusions. Low vitamin D level is an independent risk factor for muscle weakness in men aged more than 50 years. Therefore, vitamin D levels should be screened and early replacement should be initiated for the sake of improvement of muscle strength in elderly subjects that vulnerable for frailty.
  • Perspectives

    Zhang S, Ma Q, Wu X, Chen P

    LncRNA HOTTIP Promotes Ovarian Cancer Cell Invasion And Metastasis By Stabilizing Hif-1a In The Anoxic Cellular Microenvironment

    Acta Endo (Buc) 2022 18(3): 263-270 doi: 10.4183/aeb.2022.263

    Abstract
    Background. The high recurrence rate and low survival rate of ovarian cancer (OC) patients are closely related to an anoxic environment. We aim to study the mechanism of long non-coding RNA (lncRNA) HOXA transcript at the distal tip (HOTTIP) on hypoxia ovarian cancer cells (OCC) and its mechanism was investigated. Methods. Knockdown and overexpression of HOTTIP in human OCC (SKOV-3, OVCAR3) were performed. The expression levels of HOTTIP and HIF- 1α were monitored by qRT-PCR and WB. Transwell was conducted to validate the cell migration and invasion. ELISA was performed to calculate VEGF concentration in cells. Cell viability was monitored by CCK-8. Cell apoptosis and cycle were tested by flow cytometry. RNA pull-down was used to analyze the interaction between HIF-1α and HOTTIP. Results. HOTTIP was highly expressed in OCC. After HOTTIP knockdown, HIF-1α expression and VEGF concentration in OCC were decreased. Cell migration, invasion, and cell viability were decreased. Cell apoptosis rate and G0/G1 phase cells were increased. RNA pull-down indicated a direct interaction between HIF-1α and HOTTIP. Conclusions. HOTTIP formed a positive feedback loop with HIF-1α to promote the development and metastasis of hypoxia ovarian cancer. This study provided theoretical support for the development of new OC treatment strategies.
  • Images in Endocrinology

    Rickes S, Neye H

    Osteitis fibrosa cystica misdiagnosed as lytic bone metastases

    Acta Endo (Buc) 2010 6(2): 264-264 doi: 10.4183/aeb.2010.264

  • Book Review

    Rosulescu R

    Sleep Disorders Medicine: Basic Science, Technical Considerations, and Clinical Aspects

    Acta Endo (Buc) 2015 11(2): 264-267 doi: 10.4183/aeb.2015.264

  • Editorial

    Grigorie D

    Do You Frax?

    Acta Endo (Buc) 2012 8(2): 265-266 doi: 10.4183/aeb.2012.265

  • Notes & Comments

    Voicu V, Medvedovici A, Miron D, Radulescu F

    A novel approach on pharmacokinetic/pharmacodynamic correlations of risperidone: understanding its safety and efficacy profiles

    Acta Endo (Buc) 2010 6(2): 265-285 doi: 10.4183/aeb.2010.265

    Abstract
    The pharmacokinetic characteristics of a compound as well as the immediate consequences of its physicochemical behavior during interactions with biological structures,\r\nrepresent the key issues for its pharmacodynamic profile, starting from the most fundamental global aspects (i.e. central and / or peripheral action) to the most detailed ones (i.e. molecular mechanism of action).\r\nSuccessive metabolic reactions lead to either bioactivation or bioinactivation of themolecular entity. A particular importance is currently assigned to several molecular\r\nphysicochemical descriptors, for instance the polarity degree (mirroring the changes of partition coefficients and of the permeability of biological structures), and emphasizing on distribution and renal excretion rate.\r\nThe active metabolite (9-hydroxy-risperidone) of the atypical antipsychotic agent risperidone has an increased polar character and, consequently, its pharmacokinetic profile is modified compared to the parent drug: especially the penetration through the bood brain barrier and the efflux pump mediated transport were considered. In this context, the kinetic characteristics and their correlation with the pharmacodynamic properties for the two active\r\nentities, as well as the consequences dealing with the antipsychotic efficacy, the safety and efficacy profiles can be anticipated. The present approach critically asseses the available data from literature corroborated with the personal findings over the last years.